TrialBMC cancer2022

The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005).

Fangfang Duan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.